Respiratory Syncytial Virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. The role of RSV load in disease severity is still debated. We present the interim results of a prospective monocentric study enrolling previously healthy infants hospitalized for RSV bronchiolitis, collecting nasopharyngeal aspirates every 48 h from admission to discharge, and evaluating RSV load dynamics in relation to clinical outcome measures of bronchiolitis severity, including: need, type and duration of oxygen therapy, length of hospitalization, and the bronchiolitis clinical score calculated at admission. The results showed that the highest viral replication occurs within the first 48 hours after admission, with a significant decrease at subsequent time points ( < 0.0001). Moreover, higher RSV-RNA values were associated with the need for oxygen therapy ( = 0.03), particularly high-flow nasal cannula type ( = 0.04), and longer duration of respiratory support ( = 0.04). Finally, higher RSV load values were correlated with lower white blood cells, especially lymphocyte counts and C-reactive protein levels ( = 0.03, = 0.04, and = 0.01, respectively), as well as with patients of a younger age ( = 0.02). These data suggest that RSV may actively contribute to the clinical severity of bronchiolitis, together with other potential non-viral factors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221166PMC
http://dx.doi.org/10.3390/pathogens12050645DOI Listing

Publication Analysis

Top Keywords

rsv load
12
respiratory syncytial
8
rsv bronchiolitis
8
oxygen therapy
8
bronchiolitis
6
rsv
6
syncytial virus-load
4
virus-load kinetics
4
clinical
4
kinetics clinical
4

Similar Publications

Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection .

Front Cell Infect Microbiol

January 2025

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Introduction: Respiratory syncytial virus (RSV) remains a major international public health concern. However, disease treatment is limited to preventive care with monoclonal antibodies and supportive care. In this study, natural products were screened to identify novel anti-RSV inhibitors.

View Article and Find Full Text PDF

Evaluating the Impact of N-Glycan Sequon Removal in the p27 Peptide on RSV F Protein Immunogenicity and Functionality.

Viruses

November 2024

Laboratory for Microbiology, Parasitology and Hygiene, Infla-Med Centre of Excellence, University of Antwerp (UA), Universiteitsplein 1 S.7, 2610 Antwerp, Belgium.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in young children, elderly and immunocompromised patients worldwide. The RSV fusion (F) protein, which has 5-6 N-glycosylation sites depending on the strain, is a major target for vaccine development. Two to three of these sites are located in the p27 peptide, which is considered absent in virions.

View Article and Find Full Text PDF

Stability of Respiratory Syncytial Virus in Nasal Aspirate From Patients Infected With RSV.

Influenza Other Respir Viruses

December 2024

Laboratory for Drug Discovery and Disease Research, Shionogi & Co, Ltd, Osaka, Japan.

Background: Evaluation of infectious virus titer is a challenge for respiratory syncytial virus (RSV) clinical trials because of the labile nature of RSV and rapid loss of infectivity without proper specimen handling. However, there has been no rigorous investigation into RSV stability in clinical specimens.

Methods: RSV stability was investigated by evaluating virus titers and defined as titer variation from baseline within three standard deviations of our titration assay.

View Article and Find Full Text PDF

Respiratory syncytial virus (RSV) is a leading cause of respiratory infection, hospitalization and death in infants worldwide. No fully effective RSV therapy using direct antivirals is marketed. Since clinical efficacy data from naturally infected patients for such antivirals are not available yet, animal studies are indispensable to predict therapeutic intervention.

View Article and Find Full Text PDF

An air sanitizer was evaluated using an aerobiology protocol, compliant with the U.S. Environmental Protection Agency's Air Sanitizer Guidelines, for virucidal activity against bacteriophages Phi6 and MS2 (used as surrogates for enveloped and non-enveloped human pathogenic viruses).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!